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Abstract
Background: Escherichia coli accounts for 70–95% of 
community-acquired urinary tract infections (UTIs). 
Recently, there has been an increase in the prevalence 
of extended-spectrum β-lactamase (ESBL) in the com-
munity which required an accurate identification for 
better management. Therefore, the current study was 
performed to determine the antimicrobial resistance 
pattern, investigate ESBL phenotypes and genotypes 
(blaCTX-M, bla TEM and bla SHV genes) and determine 
the phylogenetic groups among ESBL-positive isolates 
from outpatients.
Methods: One hundred and eighty-three positive urine 
samples were collected from 4450 outpatient clinic attend-
ees. Antibiotic susceptibility was determined and ESBL 
phenotype screening was carried out using disk diffusion 
agar and combination disk techniques, respectively. The 
assessment of the presence of the blaCTX-M, bla TEM and 
blaSHV genes and phylogenetic grouping were performed 
using the polymerase chain reaction (PCR) method.
Results: Out of 183 E. coli isolates, 59 (32.2%) showed a 
positive ESBL phenotype. The prevalence of ESBL-pro-
ducing E. coli was higher in males (57.4%). Fifty-seven 
of the ESBL-producing strains carried at least one of 
the β-lactamase genes (bla CTX-M, bla TEM, bla SHV). 
Phylotyping of multi-drug resistant isolates indicated 
that the isolates belonged to B2, A and D phylogroups. 
 Analysis of resistance patterns among these phylogroups 
revealed that 74.4%, 55.3% and 29.7% of the isolates in 
the B2 group were resistant to trimethoprim-sulfameth-
oxazole, ciprofloxacin and gentamicin, respectively. 
Most of the strains in the phylogroup B2 carried the bla 
CTX-M gene.
Conclusions: All the ESBL-producing isolates were placed 
in one of the four phylogenetic groups. The presence of 
CTX-M and resistance to quinolones were more frequent 
in B2 strains than in non-B2 strains.
Keywords: Escherichia coli; extended spectrum 
β-lactamase (ESBL); PCR; phylogenetic groups; urinary 
tract infection.
Introduction
Urinary tract infections (UTIs) are considered to be one 
of the most important and frequent infectious diseases, 
especially among adults. Annually, 150  million UTIs 
occur around the world [1]. Escherichia coli, from the 
Enterobacteriaceae family, is the most frequent bacterial 
agent in both nosocomial and community-acquired UTIs. 
About 70–80% of all uropathogens is E. coli [1–3]. UTI is 
the second most prevalent bacterial infection in the com-
munity, and uropathogenic E. coli accounts for 70–95% of 
community-acquired UTI cases [4–6]. β-Lactam antibiot-
ics due to their broad antibacterial spectrum and minimal 
side effects are widely used in the treatment of various 
infections such as UTI [7]. Interestingly, the non-rational 
and intensive use of antibiotics by humans and animals 
is considered as one of the mechanisms that can acceler-
ate the process by which bacteria can acquire resistance 
[8]. Therefore, the overuse of antibiotics explains the 
emerging multiple drug resistance in E. coli. The resist-
ance of community-acquired E. coli to extended spectrum 
β-lactamases (ESBLs) is a particular concern for clinicians 
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and public health authorities [9]. ESBLs are a group of 
enzymes that hydrolyze oxyimino-β-lactams including 
extended-spectrum cephalosporins but excluding cepha-
mycins and carbapenems [10]. Many different types of 
ESBLs have been described until now. However, the most 
common ones are derivatives of the SHV, TEM and CTX-M 
enzymes [11]. ESBL-producing E. coli isolates are geneti-
cally diverse. Recently, the different antibacterial resist-
ance of E. coli strains among different phylogenetic groups 
has been considered as a matter of importance. Phyloge-
netic analyses have been used for the differentiation of E. 
coli strains into four major phylogenetic groups including 
A, B1, B2 and D. Three genetic markers (the ChuA, YjaA 
genes, and the DNA fragment TspE4.c2) have been used 
as a target in the triplex PCR method to describe phyloge-
netic groups [12, 13].
It is very important to identify the exact prevalence of 
ESBL-producing E. coli among Iranian patients with UTI 
infection for proper patient management. To address this 
question, as a proof of principle it is vital to determine the 
antimicrobial resistance patterns, investigate ESBL phe-
notypes and genotypes (bla CTX-M, bla TEM, bla SHV) and 
determine the phylogenetic groups among ESBL-positive 
isolates from outpatient clinics.
Materials and methods
Study design
This descriptive, cross-sectional study was conducted 
during the period from 2014 to 2016 to determine the fre-
quency of phylogenetic groups and β-lactamase genes 
(bla CTX-M, bla TEM, bla SHV) of uropathogenic E. coli in 
outpatients. Eligible subjects received detailed explana-
tions about the study, and informed consent was obtained 
from all participants.
Subjects and procedure
The study included 4450 outpatients. First-void urine 
(FVU) samples were collected in sterile urine containers 
from these patients, and immediately the samples were 
inoculated on Eosin methylene blue agar medium and 
incubated in aerobic condition at 37 °C for 24–48 h. The 
counts of 105 cfu/mL or more was considered as positive. 
Bacterial identification was made using culture character-
istics, Gram stain and biochemical tests.
Antimicrobial susceptibility testing
Reference susceptibility testing (Kirby-Bauer disk diffusion 
method) was performed using the available antibiotic disks 
(Rosco Diagnostica, Taastrup, Denmark) as recommended 
by the Clinical Laboratory Standard Institute (CLSI) [14]. 
Antibiotic disks containing cefotaxime (30 μg), ceftazidime 
(30 μg), nalidixic acid (30 μg), trimethoprime-sulfamethox-
azole (12.5/23.75 μg), amikacin (30 μg), ciprofloxacin (5 μg), 
gentamicin (10 μg), nitrofrantoin (30 μg) and imipenem (10 
μg) were tested against the identified isolates. Escherichia 
coli ATCC25922 was used as the quality control.
The test was conducted by applying a bacterial inoc-
ulum according to the 0.5 McFarland standard on the 
surface of Mueller-Hinton agar (Merck, Germany) plates. 
Nine commercially prepared, fixed concentration disks 
were placed on the inoculated agar. All plates were incu-
bated at 35 °C for 24 h, and the zones of growth inhibition 
around each of the antibiotic disks are measured to the 
nearest millimeter. The zone diameters of each drug are 
interpreted using the criteria published by the CLSI [14].
Confirmatory test for ESBL detection
All of the E. coli isolates which were resistant to cefotaxime 
(30 μg) or ceftazidime (30 μg) were subjected to ESBL screen-
ing according to the CLSI criteria. Both ceftazidime and cefo-
taxime with and without clavulanic acid (10 μg) disks were 
placed 25 mm apart from each other on Muller-Hinton agar 
inoculated with 0.5 McFarland suspension of the test isolate. 
The difference between the inhibition zone diameters of 
cefotaxime or ceftazidime disk in combination with clavu-
lanic acid was considered as a positive ESBL phenotype.
Molecular analysis
DNA extraction
Genomic DNA was extracted with AccuPrep Genomic DNA 
Extraction Kit (Bioneer, Korea) and the extraction proto-
col was followed according to the manufacturer’s instruc-
tions. The quantity of the extracted DNA was assessed 
using a spectrophotometer [15]. Then all DNA samples 
were stored at −20 °C.
PCR with β-lactamase-specific primers
The PCR reaction mixture contained 2 μL of extracted 
DNA, 12.5 μL of Taq DNA Polymerase Master Mix RED 
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(Ampliqon, Denmark), 1 μL of (bla CTX-M, bla TEM, bla 
SHV) primer pairs, 1 μL template and ddH2O up to a total 
volume of 25 μL. The PCR conditions for amplification of 
all genes were as follows: initial denaturation for 5 min at 
94 °C, 35 cycles of denaturation for 60 s at 94 °C, anneal-
ing for 60 s at 56 °C and extension for 90 s at 72 °C, with a 
final extension at 72 °C for 10 min.
Triplex PCR assay
The phylogenetic group of each ESBL-producing E. coli 
was determined according to Clerment et al. [12] by triplex 
PCR for the chuA and yjaA genes and the DNA fragment 
TSPE4.C.
Triplex PCR was performed for the rapid phylogenetic 
classification of E. coli isolates as follows: The reaction 
mixture included 1 μL of extracted DNA, 25 μL of Taq DNA 
Polymerase Master Mix RED (Ampliqon, Denmark), 0.5 μL 
of each specific oligonucleotide primers (Table 1) in a total 
volume of 50 μL.
The Triplex PCR cycling parameters were 95 °C 
for 10  min, 35 cycles of denaturation for 40  s at 95 °C, 
annealing for 40 s at 57 °C, an extension for 40 s at 72 °C, 
with a final extension of 8 min at 72 °C. Escherichia coli 
ATCC25922 was used as a control strain for each cycle.
Gel electrophoresis
All PCR products were visualized by 1.5% agarose gel 
electrophoresis in Tris-borate-ethylenediaminetetraacetic 
acid (TBE) buffer and stained with CinnaGen DNA Safe 
Stain (SinaClon BioScience Co., Iran).
Designation of different phylogenetic groups
After electrophoresis, the strains were assigned to the 
phylogenetic groups as shown in Figure 1.
Ethical considerations
The study was performed according to the Helsinki prin-
ciples of ethics. All participants were aware of the study 
purposes and signed a written informed consent.
Data analysis
Statistical analyses were performed using the Statisti-
cal Package for Social Sciences (SPSS) for Windows 16.0 
(SPSS Inc., Chicago, IL, USA).
Results
Urine samples that met the inclusion criteria of 105 colony-
forming units per milliliter were subjected to this study. 
A total of 183 non-duplicate E. coli isolates were recov-
ered from the urine specimens. The mean and standard 
deviation age of the source patients was 35.3 ± 22.35 years 
(range from 12 months to 90 years). The prevalence of UTI 
was 159 (86.88%) and 24 (13.11%) in females and males, 
respectively. There was a significant difference in UTI 
prevalence between the two sexes (p < 0.05).
Antimicrobial susceptibility testing
For the total isolates the in vitro susceptibilities to cefo-
taxime, ceftazidime, nalidixic acid, trimethoprime-sul-
famethoxazole, amikacin, ciprofloxacin, gentamicin, 
nitrofrantoin and imipenem were determined by using 
the disk diffusion assays; our present results showed that 
Table 1: Oligonucleotides used in this study.
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Figure 1: Assigning of different phylogenetic groups.
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1.63% of isolates were resistant to all antibiotics and 27.3% 
of isolates were susceptible to all antibiotics.
Out of 183 E. coli isolates, 59 (32.2%) showed a posi-
tive ESBL phenotype using the Double Disc Synergy Test 
(DDST) according to CLSI 2014 [14]. ESBL-producing E. coli 
was higher in males (57.4%) compared to females (42.6%). 
Fifty-seven (96.6%) of the ESBL-producing E. coli strains 
carried at least one of the β-lactamase genes (bla CTX-M, 
bla TEM, bla SHV).
Interestingly, two (3.4%) of the phenotypically posi-
tive ESBL strains were negative for the (bla CTX-M, bla 
TEM, bla SHV) genes.
Furthermore, the results obtained from the current 
study show a significant association between ESBL-
producing E. coli and resistance to CAZ (p < 0.001), CTX 
(p < 0.001), trimethoprim-sulfamethoxazole (p < 0.001) 
and ciprofloxacin (p < 0.05).
Fifty percent of the ESBL isolates were found to be 
sensitive to gentamicin. Resistance to trimethoprime-
sulfamethoxazole (64.4%), amikacin (59.3%) and 
ciprofloxacin (59.3%) was observed among the ESBL-
producing isolates. All the isolates were found to be 
highly susceptible to imipenem, nitrofurantoin and 
nalidixic acid.
Detection of β-lactamase genes
Detection of β-lactamase genes in 59 ESBL-producing E. 
coli isolates showed the presence of 69.5%, 47.4% and 
44% of bla CTX-M, bla TEM, bla SHV genes, respectively, 
using specific PCR primers (Figure 2). The simultaneous 
presence of two (blaCTX-M-SHV or blaCTX-M-TEM or 
blaTEM-SHV) and three ESBL genes (CTX-TEM-SHV) in 
a single isolate occurred in 25.4% and 32.2% isolates, 
respectively (Table 2).
Triplex PCR assays for phylotyping of multi-drug 
resistant isolates indicated that the isolates belonged to 
the B2, D and A phylogroups (Figure 3). ESBL-positive iso-
lates were found to be more in the phylogenetic group B2 
and less in groups A and D. In this study, no strain was 
found belonging to group B1.
Analysis of the resistance pattern among these 
phylogroups revealed that 74.4%, 55.3% and 29.7% of 
isolates in group B2  were resistant to SXT, CP and GM, 
respectively. Whereas most of the strains in phylogroup 
B2 carried the bla CTX-M gene, this result reveals that the 
bla CTX-M gene simultaneously occurs with other genes 




Figure 2: Gel electrophoresis of bla CTX-M, bla TEM, bla SHV PCR products.
Lanes A7, B1, C2 contain a 100 bp DNA ladder, lanes A2 to A5 show PCR products for four samples which were positive for the blaSHV gene 
(231 bp), lane A6 was a negative control. Lanes B2 to B6 show PCR products for five samples which were positive for blaTEM (459 bp). Lanes 
C3 and C4 show PCR results for two samples which were positive for the blaCTX-M gene (560 bp).
Table 2: Distribution of different β-lactamase gene patterns in four 
phylogroups (A, B1, B2, D).
β-Lactamase 
gene patterns
  n  A  B1  B2  D
blaCTX-M-TEM-SHV   19 (33.3%)  –  –  13 (68.4%)  6 (31.6%)
blaCTX-M-SHV   9 (15.78%)  –  –  9 (100%)  –
blaCTX-M-TEM   2 (3.5%)  –  –  2 (100%)  –
blaTEM-SHV   4 (7%)  4 (100%)  –  –  –
blaTEM   4 (7%)  –  –  4 (100%)  –
blaSHV   3 (5.26%)  –  –  3 (100%)  –
blaCTX-M   16 (28%)  –  –  16 (100%)  –
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Discussion
Clinical management of UTI is one of the most important 
aims, because E. coli strains are responsible for a high per-
centage of this infection which can acquire resistance to 
antimicrobial agents [16–18]. Several antibiotics can be 
used for the treatment of bacterial infections; however 
most general practitioners prescribe β-lactam antibiotics 
to be used as the first line of UTI treatment. Furthermore, 
due to uncontrolled consumption of antibiotics nowadays 
several bacteria have started developing resistance to this 
class of antimicrobial agents by ESBL enzymes as a mech-
anism of resistance.
The results of the present study showed that com-
munity-acquired UTI is more common in females than 
in males and the reported results are in agreement with 
previous studies [19, 20]. Despite the higher prevalence 
of UTI among the female population, we demonstrated 
in this report that 59 of our isolates carried the resistance 
gene from which 57.4% were isolated from males. The 
results of our current report is in concordance with that 
conducted by Shashwati and his associates, who studied 
the prevalence of ESBLs among the patients they attended 
at the tertiary care center; their results showed that ESBL 
producers were more in males (52.54%) than in females 
[21]. Findings of the present study and previous ones con-
firmed that male gender is one of the risk factors associ-
ated with community-acquired ESBL-positive UTI [22, 23].
Furthermore, we demonstrated in this study that ESBL-
producing isolates were resistant to other β-lactamase 
antibiotics including trimethoprim-sulfamethoxazole and 
ciprofloxacin. However, none of the isolates were found 
to be resistant to imipenem which is considered an effec-
tive drug for UTI treatment in many countries [24, 25], 
Carbapenems, including imipenem, should be kept in 
reserve for use in life-threatening infections [21]. More-
over; the results of our current report showed that more 
than 90% of our ESBL isolates were susceptible to nitro-
furantoin and nalidixic acid.
The result of genotype analyses in the present study 
showed that E. coli isolates carried different types of ESBL 
genes. Two important risk factors that increase infec-
tion by ESBL-producing isolates are the presence of more 
underlying diseases and higher antibiotic pressure. These 
risk factors usually exist in elderly patients [26].
The prevalence of β-lactamase genes is variable 
across countries, cities and regions. In the current study, 
the prevalence of bla CTX-M, bla TEM, bla SHV was 44%, 
47.4 and 69.5%, respectively [27, 28]. At the first cases of 
ESBLs, the prevalence of the TEM and SHV genes was the 
most predominant but now more CTX-M type is reported 
from several countries including Africa, India, Iran and 
industrialized countries such as France, Canada and the 
UK [29]. In the present study, the predominant ESBL gene 
in E. coli isolates was CTX-M and two isolates of positive 
phenotype ESBL isolates lacked CTX-M, SHV and TEM, 
which can be explained by the possible presence of other 
ESBL genes. In several similar studies [30, 31], the coex-
istence of different β-lactamase genes within the same 
isolates have been analyzed as well. The results showed 
that 25.4% and 32.2% of the ESBL-producing isolates carry 
two or three β-lactamase genes, respectively. Data analy-
ses revealed that CTX-M is the most prevalent ESBL; this 
finding is consistent with previous studies [31–34]. Pro-
duction of CTX-M was significantly associated with resist-
ance to most of the antibiotics.
All of the ESBL-producing isolates were placed in one 
of the four phylogenetic groups A, B1, B2 and D. Among 
Figure 3: Triplex PCR for phylogenetic groups.
Lane A, negative control; lane B, group B2; lane C, group A; lane D, group A; lane E, group D; M, 100 bp ladder.
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E. coli strains, B2 and D phylogenetic groups were the 
most prevalent in this study. This result was in accord-
ance with other studies [35, 36]. The results of two inde-
pendent studies conducted by Saeed and Dadie indicated 
that most of the isolates belonged to group A, which is in 
contrast to our study [37, 38]. This difference in the phylo-
group distribution can be due to several factors such as 
genetic, dietary, health, environmental and geographic 
conditions of the host [39–41].
According to the present findings, the presence of 
CTX-M and resistance to quinolones was more frequently 
observed in group B2 strains than in non-B2 strains which 
can be explained by simultaneous occurrence of fluoro-
quinolone resistance genes with the blaCTX-M gene which 
was observed in several studies such as in Ruppe, Juan 
and Mosquito [42–44].
In conclusion, uncontrolled consumption of 
antibiotics in the community has resulted in a high 
prevalence of ESBL-producing E. coli isolates among com-
munity-acquired urinary infections. β-Lactamase genes 
particularly CTX-M, TEM and SHV have the capacity to 
disseminate and persist in the community. In this project, 
all the ESBL-producing isolates were placed in one of the 
four phylogenetic groups. The presence of CTX-M and 
resistance to quinolones was more frequently observed 
in group B2  strains than in non-B2  strains. In addition, 
several studies are needed in various regions with a 
higher population for understanding the distribution of 
ESBL-producing E. coli in the community and for provid-
ing phylogenetic information.
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